Search
Dupilumab
go.drugbank.com/drugs/DB12159ApprovedInvestigationalDupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. … It was first approved by the FDA in 2017.
Categories: Interleukin-4 Receptor alpha Antagonist, Interleukin 4 Receptor alpha AntagonistsInterferon alfacon-1
go.drugbank.com/drugs/DB00069ApprovedWithdrawnThe 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding … Prior to final purification, Interferon alfacon-1 is allowed to oxidize to its native state, and its final purity is achieved by sequential passage over a series of chromatography columns.
Elbasvir
go.drugbank.com/drugs/DB11574Approved[synthesis] The barrier to the development of resistance to NS5A inhibitors is lower than that of NS5B inhibitors, another class of DAAs. … of SARS-CoV-2, the human coronavirus responsible for the COVID-19 pandemic.
Ciltacabtagene autoleucel
go.drugbank.com/drugs/DB16738ApprovedInvestigational[L40739] Patient T-cells are reprogrammed with a transgene encoding a specific chimeric antigen receptor (CAR) which features two BCMA-targeting single-domain antibodies. … Multiple myeloma is a malignancy involving the plasma cells of the bone marrow.
Synonyms: Autologous bi-epitope BCMA-targeted CAR T-cellsClocortolone
go.drugbank.com/drugs/DB00838ApprovedClocortolone is a medium potency corticosteroid that is often used as a topical cream for the relief of inflammatory oand pruritic (itching) arising from steroid-responsive dermatoses of the scalp.
Categories: Corticosteroid Hormone Receptor AgonistsDarifenacin
go.drugbank.com/drugs/DB00496ApprovedInvestigationalThis block reduces the urgency to urinate and so it should not be used in people with urinary retention. … It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments.
Products: ENABLEX ® 15 MG TABLETAS DE LIBERACION PROLONGADA, ENABLEX ® 7.5 MG TABLETAS DE LIBERACION PROLONGADATiclopidine
go.drugbank.com/drugs/DB00208ApprovedIt is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. … Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who cannot take aspirin or in whom aspirin has not worked to prevent a thrombotic stroke.
Categories: Purinergic P2 Receptor Antagonists, Purinergic P2Y Receptor AntagonistsL-Glutamine
go.drugbank.com/drugs/DB00130ApprovedInvestigationalNutraceuticalIt is the principal carrier of nitrogen in the body and is an important energy source for many cells. … An oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical.
Lorazepam
go.drugbank.com/drugs/DB00186ApprovedInvestigationalThe first historic FDA label approval is reported in 1985 by the company Mutual Pharm.[L5095] … [A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977.
Ertugliflozin
go.drugbank.com/drugs/DB11827ApprovedInvestigationalErtugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. … [A31581] Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.[L48621]